Published in AAPS J on September 07, 2012
Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A (2013) 1.83
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn (2013) 0.98
Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model. Front Immunol (2015) 0.97
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev (2015) 0.84
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs (2016) 0.82
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs (2015) 0.81
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT Pharmacometrics Syst Pharmacol (2016) 0.80
Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J (2014) 0.79
Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development. AAPS J (2013) 0.78
Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs (2016) 0.78
Development of Physiologically Based Pharmacokinetic Model (PBPK) of BMP2 in Mice. Biol Syst Open Access (2013) 0.77
Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodies. AAPS J (2014) 0.77
Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma. Front Physiol (2017) 0.75
Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens. MAbs (2016) 0.75
Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain. Br J Clin Pharmacol (2016) 0.75
An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats. AAPS J (2015) 0.75
Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. MAbs (2016) 0.75
Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn. MAbs (2017) 0.75
Impact of altered endogenous IgG on unspecific mAb clearance. J Pharmacokinet Pharmacodyn (2017) 0.75
Endocytic recycling. Nat Rev Mol Cell Biol (2004) 10.87
Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. J Cell Biol (1983) 6.17
Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2008) 4.17
Development trends for therapeutic antibody fragments. Nat Biotechnol (2009) 3.51
Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol (1996) 2.90
Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res (1999) 2.58
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Enhanced antibody half-life improves in vivo activity. Nat Biotechnol (2010) 2.33
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol (2006) 2.32
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol (2004) 2.30
A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med (1994) 2.27
Marketed therapeutic antibodies compendium. MAbs (2012) 2.26
Mediation of pinocytosis in cultured arterial smooth muscle and endothelial cells by platelet-derived growth factor. J Cell Biol (1978) 2.16
Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem (2003) 2.03
Antibody-based therapeutics to watch in 2011. MAbs (2011) 2.00
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol (1998) 1.96
Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol (2009) 1.93
An engineered human IgG1 antibody with longer serum half-life. J Immunol (2006) 1.88
Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry (1995) 1.87
Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol (2007) 1.86
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn (2007) 1.82
Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel (2010) 1.64
Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci U S A (2009) 1.54
Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol (2003) 1.50
Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res (1994) 1.45
Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol (1997) 1.45
Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res (1997) 1.44
Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem (2006) 1.42
Kinetics of endosome acidification in mutant and wild-type Chinese hamster ovary cells. J Cell Biol (1987) 1.42
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol (2005) 1.42
Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos (2010) 1.38
Regulation of the V-ATPase along the endocytic pathway occurs through reversible subunit association and membrane localization. PLoS One (2008) 1.38
Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res (1986) 1.36
Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res (1995) 1.35
Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem (2010) 1.32
Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos (2006) 1.28
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A (2006) 1.26
Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I antigen homolog. Cold Spring Harb Symp Quant Biol (1989) 1.18
A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng (2005) 1.18
Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci (2010) 1.15
A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res (2010) 1.10
High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. Biochemistry (1997) 1.10
FcRn mediates elongated serum half-life of human IgG in cattle. Int Immunol (2006) 1.03
Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res (1996) 0.99
Enhanced rates of fluid pinocytosis during exponential growth and monolayer regeneration by cultured arterial endothelial cells. J Cell Physiol (1980) 0.94
Effects of mycophenolic acid (MPA) treatment on expression of Fc receptor (FcRn) and polymeric immunoglobulin receptor (pIgR) mRNA in adult sheep tissues. Croat Med J (2004) 0.82
Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia (2002) 0.81
Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci (2004) 4.28
Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood (2002) 2.65
Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost (2002) 1.90
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn (2007) 1.82
Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci (2002) 1.16
Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci (2010) 1.15
Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Hum Immunol (2005) 1.07
Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci (2003) 1.07
Investigation of the influence of FcRn on the distribution of IgG to the brain. AAPS J (2009) 1.00
Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn (2013) 0.98
Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. Cancer Chemother Pharmacol (2011) 0.94
Mechanisms of IVIG action in immune thrombocytopenic purpura. Clin Lab (2004) 0.93
Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. J Pharm Sci (2005) 0.91
Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. J Pharm Sci (2003) 0.89
Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther (2009) 0.88
Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice. J Pharm Sci (2003) 0.87
Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.86
Investigation of the role of FcγR and FcRn in mAb distribution to the brain. Mol Pharm (2012) 0.84
Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. J Pharm Sci (2007) 0.83
Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. Int J Pharm (2012) 0.83
Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts. AAPS J (2012) 0.82
Physiologically based pharmacokinetic model for topotecan in mice. J Pharmacokinet Pharmacodyn (2010) 0.82
Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood (2006) 0.82
Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice. J Pharmacokinet Pharmacodyn (2007) 0.81
Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer. J Pharmacokinet Pharmacodyn (2012) 0.81
High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.80
Nano-scale liquid chromatography/mass spectrometry and on-the-fly orthogonal array optimization for quantification of therapeutic monoclonal antibodies and the application in preclinical analysis. J Chromatogr A (2012) 0.80
Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenografts. MAbs (2010) 0.80
Application of anti-methotrexate Fab fragments for the optimization of intraperitoneal methotrexate therapy in a murine model of peritoneal cancer. J Pharm Sci (2005) 0.79
IVIG effects on autoantibody elimination. Allergy (2004) 0.79
Investigation of antibody-coated liposomes as a new treatment for immune thrombocytopenia. Int J Pharm (2005) 0.78
An ELISA for quantification of T84.66, a monoclonal anti-CEA antibody, in mouse plasma. J Immunoassay Immunochem (2010) 0.78
Pharmacokinetic and pharmacodynamic effects of high-dose monoclonal antibody therapy in a rat model of immune thrombocytopenia. AAPS J (2006) 0.77
Development and validation of enzyme-linked immunosorbent assays for quantification of anti-methotrexate IgG and Fab in mouse and rat plasma. J Immunoassay Immunochem (2004) 0.77
Development and validation of an enzyme linked immunosorbent assay for the quantification of carcinoembryonic antigen in mouse plasma. J Immunoassay Immunochem (2009) 0.77
Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy. Pharm Res (2013) 0.76
Prediction of drug bioavailability in humans using immobilized artificial membrane phosphatidylcholine column chromatography and in vitro hepatic metabolic clearance. Biomed Chromatogr (2009) 0.76
Assessments of antibody biodistribution. J Clin Pharmacol (2015) 0.76
Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan. J Pharmacokinet Pharmacodyn (2013) 0.75
Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody. Int J Pharm (2013) 0.75
A GPIIb/IIIa bioreactor for specific treatment of immune thrombocytopenic purpura, an autoimmune disease. Preparation, in vitro characterization, and preliminary proof-of-concept animal studies. J Biomed Mater Res A (2005) 0.75
Pharmacodynamics of in vivo nitroglycerin tolerance in normal conscious rats: effects of dose and dosing protocol. Pharm Res (2004) 0.75
Strategies for improving the functionality of an affinity bioreactor. Int J Pharm (2005) 0.75
Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling. Cancer Chemother Pharmacol (2010) 0.75
Determination of roxatidine in human plasma by liquid chromatography/electrospray mass spectrometry and application to a clinical pharmacokinetic study. Rapid Commun Mass Spectrom (2007) 0.75